Somewhat Positive Press Coverage Somewhat Unlikely to Impact Syros Pharmaceuticals (SYRS) Stock Price
News headlines about Syros Pharmaceuticals (NASDAQ:SYRS) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Syros Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.4493485760467 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern’s analysis:
- BRIEF-Syros receives FDA Orphan drug designation for SY-1425 for treatment of AML (reuters.com)
- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Experiences Heavier than Usual Trading Volume (highlightpress.com)
- Syros Pharma Wins Orphan Designation From FDA (finance.yahoo.com)
- Syros Pharmaceuticals’ (SYRS) Buy Rating Reiterated at Cann (americanbankingnews.com)
- Syros Pharmaceuticals : Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML (4-traders.com)
Several equities analysts recently commented on SYRS shares. ValuEngine upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Cann reiterated a “buy” rating and issued a $28.00 target price on shares of Syros Pharmaceuticals in a research note on Monday. Zacks Investment Research lowered Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Cowen and Company restated a “buy” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, August 9th. Finally, JMP Securities lowered Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 10th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $20.81.
Shares of Syros Pharmaceuticals (NASDAQ SYRS) traded down 1.41% on Friday, reaching $19.55. The company had a trading volume of 18,427 shares. Syros Pharmaceuticals has a 52-week low of $10.22 and a 52-week high of $24.38. The company has a 50-day moving average price of $20.22 and a 200-day moving average price of $16.02. The firm’s market capitalization is $513.38 million.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.03. Equities research analysts forecast that Syros Pharmaceuticals will post ($2.09) EPS for the current fiscal year.
In other news, insider Eric R. Olson sold 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $21.85, for a total transaction of $273,125.00. Following the transaction, the insider now directly owns 12,500 shares of the company’s stock, valued at $273,125. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard A. Young sold 3,282 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $22.09, for a total transaction of $72,499.38. Following the transaction, the director now directly owns 423,383 shares in the company, valued at $9,352,530.47. The disclosure for this sale can be found here. Insiders have sold 21,564 shares of company stock worth $476,803 over the last ninety days.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Syros Pharmaceuticals (SYRS) Stock Price” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/25/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-syros-pharmaceuticals-syrs-stock-price.html.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.